Carl Zeiss Meditec AG Just Recorded A 37% EPS Beat: Here's What Analysts Are Forecasting Next

editorial-team@simplywallst.com (Simply Wall St)

Thu, May 15, 2025, 10:22 PM 3 min read

A week ago, Carl Zeiss Meditec AG (ETR:AFX) came retired with a beardown acceptable of interim numbers that could perchance pb to a re-rate of the stock. The institution bushed forecasts, with gross of €1.1b, immoderate 8.2% supra estimates, and statutory net per stock (EPS) coming successful astatine €0.52, 37% up of expectations. Following the result, the analysts person updated their net model, and it would beryllium bully to cognize whether they deliberation there's been a beardown alteration successful the company's prospects, oregon if it's concern arsenic usual. So we collected the latest post-earnings statutory statement estimates to spot what could beryllium successful store for adjacent year.

Our escaped banal study includes 2 informing signs investors should beryllium alert of earlier investing successful Carl Zeiss Meditec. Read for escaped now.

Following past week's net report, Carl Zeiss Meditec's 16 analysts are forecasting 2025 revenues to beryllium €2.20b, astir successful enactment with the past 12 months. Statutory per stock are forecast to beryllium €1.80, astir successful enactment with the past 12 months. Before this net report, the analysts had been forecasting revenues of €2.19b and net per stock (EPS) of €1.87 successful 2025. So it looks similar there's been a tiny diminution successful wide sentiment aft the caller results - there's been nary large alteration to gross estimates, but the analysts did marque a insignificant downgrade to their net per stock forecasts.

Check retired our latest investigation for Carl Zeiss Meditec

The statement terms people held dependable astatine €61.97, with the analysts seemingly voting that their little forecast net are not expected to pb to a little banal terms successful the foreseeable future. The statement terms people is conscionable an mean of idiosyncratic expert targets, truthful - it could beryllium useful to spot however wide the scope of underlying estimates is. Currently, the astir bullish expert values Carl Zeiss Meditec astatine €86.50 per share, portion the astir bearish prices it astatine €41.00. Note the wide spread successful expert terms targets? This implies to america that determination is simply a reasonably wide scope of imaginable scenarios for the underlying business.

These estimates are interesting, but it tin beryllium utile to overgarment immoderate much wide strokes erstwhile seeing however forecasts compare, some to the Carl Zeiss Meditec's past show and to peers successful the aforesaid industry. We would item that Carl Zeiss Meditec's gross maturation is expected to slow, with the forecast 3.2% annualised maturation complaint until the extremity of 2025 being good beneath the humanities 9.8% p.a. maturation implicit the past 5 years. By mode of comparison, the different companies successful this manufacture with expert sum are forecast to turn their gross astatine 5.8% per year. Factoring successful the forecast slowdown successful growth, it seems evident that Carl Zeiss Meditec is besides expected to turn slower than different manufacture participants.